PO-1478 Sexual concerns in cancer patients in a tertiary center.

2021 ◽  
Vol 161 ◽  
pp. S1211-S1212
Author(s):  
M. Ruza ◽  
Y. Ramírez ◽  
N.A. Linares ◽  
C. Iglesias ◽  
J.M. Rico
Keyword(s):  
Cancer Patients ◽  
Tertiary Center ◽  
Sexual Concerns

scholarly journals Attitudes, Belief, and Barriers of Indonesian Oncology Nurses on Providing Assistance to Overcome Sexuality Problem

2017 ◽  
Vol 7 (1) ◽  
pp. 15 ◽  
Author(s):  
Yati Afiyanti
Keyword(s):  
Quality Of Life ◽  
Cancer Patients ◽  
Nursing Care ◽  
Nurse Educators ◽  
Sampling Method ◽  
Oncology Nurses ◽  
Nursing Profession ◽  
Attitudes And Beliefs ◽  
Sexual Concerns

Background: Sexuality and problems related to sexuality have been identified as components of nursing care by the nursing profession, nurse educators, other disciplines and patients.Purpose: This study aimed to describe the attitudes and beliefs of the Indonesian oncology nurses towards providing sexual care for the patients with cancer.Methods: The study used a descriptive design. Using convenient sampling method, 135 oncology nurses from three hospitals in Jakarta, Indonesia participated in this study.Results: Over 85% of the nurses believed that discussing sexuality with patients is a taboo and private issue. More than 90% of nurses understood that giving a patient permission to talk about sexual concerns is a nursing responsibility. About 73.3% nurses had beliefs that most hospitalized patients are too sick to be interested in sexuality and agreed that sexuality should be discussed if only the patient initiates it. However, more than 70% of the nurses believed that the patients expect nurses to ask about their sexual concerns.Conclusion: This study revealed that inappropriate attitude and belief of nurses on sexuality aspect of their patients might become a barrier in facilitating the needs of cancer patients to manage the sexuality problem caused by cancer and the treatment. Nurses need to overcome those various barriers so that they can increase the quality of life of the cancer patients.

Pre-treatment pulmonary function testing as a predictor of cardiopulmonary toxicity in esophageal cancer patients treated with trimodality therapy.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 121-121
Author(s):  
Na Lu Smith ◽  
Christopher Leigh Hallemeier ◽  
Grant M. Spears ◽  
Thorvardur Ragnar Halfdanarson ◽  
Michelle A. Neben-Wittich ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Pulmonary Function ◽  
Cancer Patients ◽  
Pulmonary Toxicity ◽  
Univariate Analysis ◽  
Pulmonary Function Testing ◽  
Trimodality Therapy ◽  
Tertiary Center ◽  
Pre Treatment ◽  
Function Testing

121 Background: We evaluated the role of pre-treatment pulmonary function testing (PFT) in predicting the likelihood of cardiac and/or pulmonary toxicity for esophagus cancer patients receiving trimodality therapy. Methods: From 2007 to 2013, 64 patients with esophageal cancer received trimodality therapy at a single tertiary center with pre-treatment PFTs. The odds ratio of pre-treatment PFT as a predictor of cardiopulmonary toxicity was assess with univariate analysis (UVA). FEV1 (forced expiratory volume in 1 second) and DLCO (diffusion capacity for carbon monoxide) were assessed per 0.5-unit decrease. Percent FEV1 and DLCO predicted were assessed per 10% decrease. Results: The median age was 62 years (range, 41-79) with 88% male patients. A total of 70% of patients had adenocarcinoma with 66% having stage 3 disease. Most patients were former (43%) or current smokers (32%) and 18% had COPD. One or more cardiac comorbidities were observed in 54% of patients. The median RT dose was 50 Gy and the most frequent concurrent chemotherapy was cisplatin/5FU (53%). The median pre-treatment FEV1 and DLCO was 2.8 liters (range, 1-4.9) and 22.5 mL/min/mmHg (range, 17.2-25.5), respectively. This correlated to a median percent predicted value for FEV1 and DLCO of 85% (range, 30-124%) and 81.5% (range, 49-119%), respectively. The overall rate of any cardiac and pulmonary toxicity was 35% and 50%, respectively. Percent predicted value of both FEV1 and DLCO was statistically associated with pulmonary but not cardiac toxicity (Table). Conclusions: Patients with compromised pre-treatment pulmonary function are at higher risk of developing post-treatment pulmonary toxicities. Pulmonary function testing should be routinely performed prior to initiation of trimodality therapy for patient risk stratification. [Table: see text]

scholarly journals The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective

2021 ◽  
Author(s):  
Katharina Knoll ◽  
Elisabeth Reiser ◽  
Katharina Leitner ◽  
Johanna Kögl ◽  
Christoph Ebner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Gynecological Cancer ◽  
Performance Status ◽  
Tumor Stage ◽  
Breast Cancers ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Tertiary Center ◽  
The Impact

Abstract Purpose The aim of the present study was to assess the impact of postponed screening examinations and lockdown measures on gynecological and breast cancer diagnoses throughout the year 2020 in a gynecological oncological center in Austria. Methods Data of 889 patients with either newly diagnosed gynecological or breast cancer between January 2019 and December 2020 were collected. Clinical parameters including symptoms, performance status, comorbidities and referral status were compared in patients, who were newly diagnosed with cancer in the period of the first lockdown from March 2020 to April 2020 and the second lockdown from November 2020 to December 2020 and compared to the same period in 2019. Results Our results showed a strong decline in newly diagnosed cancers during the lockdown periods: −45% in gynecological cancer and -52% in breast cancer compared to the same period in 2019. Compared to the analogue period of 2019, breast cancer patients reported significantly more tumor-associated symptoms (55% vs. 31%, p = 0.013) during and in between (48% vs. 32%, p = 0.022) the lockdowns. During the lockdown, periods in the group of breast cancer patients’ tumor stage varied significantly compared to 2019 (T2–T4; p = 0.047). Conclusion Both lockdowns led to a strong decrease in newly diagnosed gynecological and breast cancers. Treatment delays in potentially curable disease could lead to inferior clinical outcomes, with the risk of missing the optimal treatment window. As the COVID-19 pandemic will be a challenge for some time to come, new strategies in patient care are needed to optimize cancer screening and management during the pandemic.

scholarly journals The Impact of COVID-19 Pandemic on Gynecological and Breast Cancer Detection Rate: A Tertiary Center Perspective.

2021 ◽  
Author(s):  
Katharina Knoll ◽  
Elisabeth Reiser ◽  
Katharina Leitner ◽  
Johanna Kögl ◽  
Christoph Ebner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Detection ◽  
Detection Rate ◽  
Cancer Detection Rate ◽  
Breast Cancer Detection ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Tertiary Center ◽  
The Impact

Abstract Purpose: The aim of the present study was to assess the impact of postponed screening examinations and lockdown measures on gynecological and breast cancer detection rate throughout the year 2020 in a gynecological oncological center in Austria.Methods: Data of 889 patients with either newly diagnosed gynecological or breast cancer between January 2019 and December 2020 were collected. Clinical parameters including symptoms, performance status, comorbidities and referral status were compared in patients, who were newly diagnosed with cancer in the period of the first lockdown from March 2020 – April 2020 and the second lockdown from November 2020 – December 2020 and compared to the same period in 2019.Results: Our results showed a strong decline in newly diagnosed cancers during the lockdown periods: -45% in gynecological cancer and -52% in breast cancer compared to the same period in 2019. Compared to the analogue period of 2019, breast cancer patients reported significantly more tumor-associated symptoms (55% versus 31%, p=0.013) during and in between (48% versus 32%, p=0.022) the lockdowns. During the lockdown periods breast cancer patients were diagnosed with a significantly higher tumor-stage (T2-T4; p=0.047).Conclusion: Both lockdowns led to a strong decrease in newly diagnosed gynecological and breast cancers. Treatment delays in potentially curable disease could lead to inferior clinical outcomes, with the risk of missing the optimal treatment window. As the COVID-19 pandemic will be a challenge for some time to come, new strategies in patient care are needed to optimize cancer screening and management during the pandemic.

Brain cancer and sexual health: A case report

2004 ◽  
Vol 2 (3) ◽  
pp. 315-318 ◽  
Author(s):  
MICHAEL L. KRYCHMAN ◽  
ALISON AMSTERDAM ◽  
JEANNE CARTER ◽  
MERCEDES CASTIEL ◽  
LISA DeANGELIS
Keyword(s):  
Case Report ◽  
Sexual Health ◽  
Cancer Patients ◽  
Brain Cancer ◽  
Terminal Illness ◽  
Clinical Signs ◽  
Recovery Phase ◽  
Laboratory Evaluation ◽  
Cancer Center ◽  
Sexual Concerns

Objective: Cancer patients often encounter sexual concerns during the diagnosing, treatment, and recovery phase of their illness. However, the sexual concerns of these patients are often overlooked. Brain cancer patients are no exception to this oversight.Methods: A case report of a 39-year-old patient with a history of high-grade anaplastic astrocytoma presented to the Sexual Health Program at the Memorial Sloan-Kettering Cancer Center complaining of vaginal discharge and several months of amenorrhea. Although the patient was administered extensive aggressive antineoplastic treatments, her disease rapidly progressed.Results: Despite the patient's terminal illness she continued to have normal sexual thoughts, feelings, and desires; however, she had difficulty discussing these issues with her partner and caregiver, who was her mother. An examination by the sexual medicine gynecologist noted no clinical signs of genital infections; however, there was minimal vaginal atrophy. Her sexual health laboratory evaluation was extensively abnormal. Her treatment consisted of intravaginal non-hormonal moisturizers and vaginal lubricants, counseling, and sexual education. The patient successfully engaged in sexual contact with her partner by the third counseling session.Significance of Results: Almost all oncology patients have sexual concerns during or following cancer treatment. These patients should be referred to comprehensive sexual health programs for treatment, if available.

Sign in / Sign up

Export Citation Format

Share Document